Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Circ Cardiovasc Genet. 2014 Nov 3;7(6):903–910. doi: 10.1161/CIRCGENETICS.114.000533

Figure 6.

Figure 6

Blood pressure was recorded throughout the treatment period, starting 2–4 days after gavage with MMF or water. BP increased progressively in untreated SHR-A3, while MMF-treated SHR-A3 maintained BP. Significant differences in BP in treated versus untreated SHR-A3 animals emerged after 2 weeks of treatment and were sustained for the rest of the study. BP in MMF-treated SHR-A3 animals was lower than in untreated SHR-A3, but remained higher than in SHR-B2 animals. In MMF-treated SHR-B2 animals, only small changes in blood pressure were noted that were significant only at 4 weeks of treatment (NS = not significant, * = p<0.05. ** = p<0.01. *** = p< 0001). Group sizes: SHR-A3 control n = 10, SHR-A3 MMF treated n = 10, SHR-B2 control n = 8, SHR-B2 MMF treated n = 9. Polynomial regression (degree 2) analysis of the blood pressure trends over time was performed using R. Coefficient values and their significance are included as supplemental data.